Trial Profile
A multi-centre, open-label study to determine the safety, tolerability and pharmacodynamics of orally administered 3,5-diiodothyropropionic acid (DITPA) in patients aged 3 to 12 with Allan-Herndon-Dudley Syndrome (AHDS)
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs DITPA (Primary)
- Indications Allan-Herndon-Dudley syndrome
- Focus Adverse reactions; Biomarker
- Acronyms DITPA01-10
- Sponsors Zarion Pharmaceuticals
- 25 Jun 2012 New trial record